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ca125 in predicting epithelial ovarian cancer:
A meta-analysis
Fake Li1†, Ruxiu Tie1†, Kai Chang1, Feng Wang1, Shaoli Deng1, Weiping Lu1, Lili Yu2* and Ming Chen1*Abstract
Backgrounds: Risk for Ovarian Malignancy Algorithm (ROMA) and Human epididymis protein 4 (HE4) appear to be
promising predictors for epithelial ovarian cancer (EOC), however, conflicting results exist in the diagnostic
performance comparison among ROMA, HE4 and CA125.
Methods: Remote databases (MEDLINE/PUBMED, EMBASE, Web of Science, Google Scholar, the Cochrane Library
and ClinicalTrials.gov) and full texts bibliography were searched for relevant abstracts. All studies included were
closely assessed with the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2). EOC predictive value of
ROMA was systematically evaluated, and comparison among the predictive performances of ROMA, HE4 and CA125
were conducted within the same population. Sensitivity, specificity, DOR (diagnostic odds ratio), LR ± (positive and
negative likelihood ratio) and AUC (area under receiver operating characteristic-curve) were summarized with a
bivariate model. Subgroup analysis and sensitivity analysis were used to explore the heterogeneity.
Results: Data of 7792 tests were retrieved from 11 studies. The overall estimates of ROMA for EOC predicting were:
sensitivity (0.89, 95% CI 0.84-0.93), specificity (0.83, 95% CI 0.77-0.88), and AUC (0.93, 95% CI 0.90-0.95). Comparison
of EOC predictive value between HE4 and CA125 found, specificity: HE4 (0.93, 95% CI 0.87-0.96) > CA125 (0.84, 95%
CI 0.76-0.90); AUC: CA125 (0.88, 95% CI 0.85-0.91) > HE4 (0.82, 95% CI 0.78-0.85). Comparison of OC predictive value
between HE4 and CA125 found, AUC: CA125 (0.89, 95% CI 0.85-0.91) > HE4 (0.79, 95% CI 0.76-0.83). Comparison
among the three tests for EOC prediction found, sensitivity: ROMA (0.86, 95%CI 0.81-0.91) >HE4 (0.80, 95% CI 0.73-0.85);
specificity: HE4 (0.94, 95% CI 0.90-0.96) > ROMA (0.84, 95% CI 0.79-0.88) >CA125 (0.78, 95%CI 0.73-0.83).
Conclusions: ROMA is helpful for distinguishing epithelial ovarian cancer from benign pelvic mass. HE4 is not better than
CA125 either for EOC or OC prediction. ROMA is promising predictors of epithelial ovarian cancer to replace CA125, but its
utilization requires further exploration.Background
Ovarian cancer is the leading cause of death from gyne-
cologic cancers in the United States and the fifth-top
cause of cancer death in women (Link 1). Non-specific
clinical manifestation mainly hinders the early diagnosis
of ovarian cancer[1]. Cancer antigen 125 (CA125) was* Correspondence: lililiyuyu@sina.com; chenming1971@yahoo.com
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reproduction in any medium, provided the orthe only FDA-approved biomarker for ovarian cancer
before the year 2008. CA125 is indicated for use as an
aid in the detection of residual ovarian carcinoma in
patients who have undergone first-line therapy and
would be considered for diagnostic second-look pro-
cedures. Although the CA125 serum level elevated in
80% of epithelial ovarian cancer (EOC) patients with
advanced stage [2], it increased in only 50% of patients
with stage I EOC [3]. In addition, CA125 serum levels
elevate in various benign gynecological diseases (includ-
ing endometriosis) [4], non-gynecologic malignancies
[5]. Therefore, considerable efforts are underway tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Flowchart of selection of eligible studies.
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http://www.biomedcentral.com/1471-2407/12/258identify new serum biomarkers, alone or combining with
CA125 to improve EOC detection [6,7].
With high-throughput technologies employed, a large
number of new biomarkers have been discovered [8-10].
Human epididymis protein 4 (HE4) is among the most
promising ones [11]. High levels of HE4 are found in
the serum of patients with EOC, especially in serous
and endometroid cancers [12]. Unlike CA125, HE4
doesn’t overexpress in endometriosis and other benign
gynecological diseases [11]. And HE4, as an aid in moni-
toring recurrence or progressive disease in patients with
epithelial ovarian cancer, has been the first biomarker
for EOC after CA125 to be approved by the U.S. Food
and Drug Administration (FDA) at the year of 2008.
However, conflicts arise on the sensitivity of HE4 and
CA125 [5,13-16].
Moore and colleagues [17] have explored a multiana-
lytes assay named the Risk of Ovarian Malignancy Algo-
rithm (ROMA™), which combines the results of HE4
EIA (enzyme immunoassay), ARCHITECT CA 125 II™
and menopausal status into a numerical score to predict
malignancy when an ovarian mass was found clinically.
Although ROMA™ has received clearance from the FDA
of U.S. in September of the year 2011, the diagnostic
accuracy of ROMA compared to CA125 and HE4 alone
is still controversial [13,16-18]. Here we try to clarify
conflicting results existing in the diagnostic accuracy of
ROMA, and in the performance comparison among
ROMA, HE4 and CA125.
Methods
Data sources and search strategy
We followed the Meta-analysis Of Observational Studies
in Epidemiology (MOOSE)[19] and the Cochrane Hand-
book for Systematic Reviews of Diagnostic Test Accur-
acy (Link 2). MEDLINE (through PubMed interface),
EMBASE, Web of Science, Google Scholar, the Cochrane
Library and ClinicalTrials.gov (ended on 22th December,
2011) were searched. Reference lists of articles identified
were manually searched. Publication languages were not
limited. The terminology for search was based on the stan-
dardized National Library of Medicine MeSH terms and
free texts. The search strategies of all the databases were
based on those of PubMed (Additional file 1: Table S1).
Two authors (RXT and WPL) independently screened
the search results based on the titles and abstracts. The
full text of selected articles were reviewed independently
by another two authors (KC and LLY) to determine the
inclusion. Disagreements were resolved by referring to a
third author (MC).
Inclusion criteria
Studies that investigated both serum HE4 and CA125 as
diagnostic tests or calculated the ROMA algorithm wereincluded if (1) they were cross-sectional studies; and
(2) performed in the same population presenting pelvic
mass; (3) all serum specimens were collected preope-
ratively; (4) all subjects with histological diagnostic infor-
mation; (5) with sufficient data for reconstructing
fourfold table.
Studies recruiting participants without presenting pel-
vis mass, with obviously error data or ROC curve ana-
lysis containing healthy person and case–control studies
were excluded. Case–control studies were excluded, for
these studies had a tendency of overestimating or under-
estimating the diagnostic performance of a test [20].
Data extraction
The data extracted from each study included: author;
year; country; design; recruitment; age; menopausal status;
test methods (e.g. chemilumenesence immunoassay);
number of patients; sensitivity; specificity and cut-off
value. Four fold tables were reconstructed. Two reviewers
(FKL and RXT) independently extracted the data for each
study and referred to a third opinion (MC) when dis-
agreements appeared. Important data that were not pro-
vided in the original studies were referred to their authors
through Emails.
Index tests and reference standard
Since the Risk of Ovarian Malignancy Algorithm
(ROMA™) is a qualitative serum test that combines the
results of HE4 EIA (enzyme immunometric assays),
ARCHITECT CA 125 II™ and menopausal status into
a numerical score. Index tests for HE4 and CA125 in
Table 1 Characteristics of studies included in the analysis




Index Tests (Methods) Cut-off Value Proven cancer N (%)
Abdel-Azeez et al., 2010 Egypt Cross-section 65 18/47 HE4 (EIA); CA125 (ECLIA) HE4: M; CA125: 35U/mL OC: 41 (63.1%)
Bandiera et al., 2011 Italy Cross-section 419 134/284 (1 patient with unknown
stage was not analyzed)
ROMA ROM reM 7.4% postM 25.3%; EOC: 114 (27.2%)
HE4 (CMIA); HE4: M 70pM, postM 140pM;
CA125 (CMIA) CA12 5U/mL
Chang et al., 2011 China Cross-section 118 - HE4 (EIA); CA125 (EIA) HE4: pM; CA125: 35U/mL OC: 52 (44.1%)
Holcomb et al., 2011 USA Cross-section 229 229/- HE4 (CMIA); CA125 (CMIA) HE4: M; CA125: 35U/mL EOC: 18 (7.86%)
Jacob et al., 2011 Switzerland Cross-section 160 84/76 ROMA ROM 3.1% EOC: 29 (18.1%)
HE4 (ELISA); CA125 (ELISA) HE4: M; CA125: 35U/mL OC: 56 (35%)
Kim et al., 2011 Korea Cross-section 159 51/108 ROMA ROM reM 7.6% postM 10.9%; EOC: 72 (45.3%)
HE4 (CMIA); CA125 (CMIA) HE4: M; CA125: 35 IU/mL OC: 78 (49.1%)
Montagnana et al., 2011 Italy Cross-section 104 51/53 ROMA ROM reM12.5% postM14.4%; EOC: 55 (52.9%)
HE4 (EIA); CA125 (CLEIA) HE4: 2pM; CA125: 35U/mL
Moore et al., 2008 USA Cross-section 233 - HE4 (EIA); CA125 (RIA) - EOC: 67 (28.8%)
Moore et al., 2009 USA Cross-section 531 248/283 ROMA ROM reM 13.1% postM 27.7% EOC: 129 (26.8%)
HE4 (EIA); CA125 (CMIA) OC: 154 (29.0%)
Moore et al., 2011 USA Cross-section 472 255/217 ROMA ROM reM 13.1%; postM 27.7% EOC: 48 (10.2%)
HE4 (ELISA); CA125 (CMIA)
Van Gorp et al., 2011 Belgium Cross-section 389 184/205 ROMA ROM reM 12.5% postM 14.4%; OC: 161 (41.4%)
HE4 (EIA); CA125 (EIA) HE4: M;CA125: 35U/mL
PreM: premenopause; PostM: postmenopause; ROMA: Risk of Ovarian Malignancy Algorithm; HE4: Human Epididymis Protein 4; CA125: Cancer Antigen 125; EO pithelial ovarian cancer; OC: ovarian cancer;
EIA: enzyme immunoassay; CLEIA: chemilumenscence enzyme immunoassay; CMIA: chemiluminescent microparticle immunoassay; ECLIA: electrochemilumensc e immunoassay; RIA: radioimmunoassay; ELISA:

































Figure 2 Graph of QUADAS-2 quality items results. Figure 2a.
Proportion of studies with low, high, or unclear risk of bias.
Figure 2b. Proportion of studies with low, high, or unclear Concerns
Regarding Applicability. Three horizontal bars represented index
tests HE4, CA125 and ROMA, respectively.
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http://www.biomedcentral.com/1471-2407/12/258this meta-analysis questions were specified as EIAs and
chemilumenesence immunoassays respectively. ROMA
algorithm is the following [17]:
Premenopausal : predictive index PIð Þ ¼ 12:0
þ 2:38 LN HE4ð Þð Þ
þ 0:0626 LN CA125ð Þð Þ
Postmenopausal : PI ¼ 8:09
þ 1:04 LN HE4ð Þð Þ
þ 0:732 LN CA125ð Þð Þ
Predicted probability : PPð Þ ¼ 100 exp PIð Þ= 1þ exp PIð Þð Þ
Reference standard was based on outcomes of histo-
pathological diagnosis. In all studies, ovarian cancer sur-
gical stages were referred to criteria from FIGO
(International Federation of Gynecology and Obsterics)
[21] (Link 3). Early stage were defined as FIGO stages I
& II, while advanced stage were FIGO stages III & IV.
Methodological quality assessment
The methodological quality of each study was evaluated
with QUADAS-2 (Quality Assessment of Diagnostic
Accuracy Studies 2) [22] quality items. Overall scores
were not helpful for interpreting study quality [23] and
were avoided in studies evaluation by QUADAS-2 tool.
Doubts were resolved by discussion. In the items of
QUADAS-2, the blindness of index tests and reference
test has been list, but not the blindness between index
tests. So one item that focus on validity of this compara-
tive question has been added in Risk of Bias part of Do-
main 2 (Index Test) in QUADAS-2 [22] as follows.
“Were the results of index tests interpreted without
knowledge of each other?” The answers (Yes, No or
Unclear) of this question were considered to help asses-
sing the Risk of Bias of including studies. According to
the suggestion in Concerns Regarding Applicability part
of Domain 2 (Index Test) in QUADAS-2 [22], variations
in test technology, executing, or interpretation might
affect estimates of the diagnostic accuracy of a test.
If index test methods varied from those specified in the
review question, concerns about applicability might exist.
Index tests for HE4 and CA125 in this meta-analysis
questions were specified as EIAs and chemilumenesence
immunoassays respectively. For tests of HE4, the chemi-
lumenesence immunoassays were more sensitive than
the specified EIAs, thus bias might be introduced into
pooling of studies. And similarly, for CA125, EIA and
RIA (radioimmunoassay) assays were less sensitive and
steady than chemilumenesence immunoassays, so stud-
ies using either EIA or RIA will be considered as High
Concern Regarding Applicability. The ROMA test
employed the results from tests of CA125 and HE4within the same study. So ROMA was considered
as High Concern Regarding Applicability when either
HE4 or CA125 test was evaluated as High Concern
Regarding Applicability.
Data analysis plan
The statistical analysis is based on the following steps:
(1) qualitatively describing the findings; (2) searching for
heterogeneity and threshold effect; (3) figuring out the
sources of heterogeneity by subgroup analysis; (4) choos-
ing appropriate model and pooling estimates statistically.
Univariate [24] and bivariate model [25] were two
choices for diagnostic meta-analysis. When a positive
correlation existed between true positive rate (TPR) and
false positive rate (FPR), the bivariate analysis model was
more appropriate [26].
Heterogeneity of studies were shown with forest
graphs and explored with I2 estimates [27]. The main
Table 2 QUADAS-2 quality items results











Abdel-Azeez et al., 2010 ? ? ? ? ☺ ☺ ☺ - ☺
Bandiera et al., 2011 ☻ ? ? ☻ ☻ ☻ ☺ ☻ ☺
Chang et al., 2011 ? ☺ ☺ ? ☺ ☺ ☻ - ?
Holcomb et al., 2011 ☻ ☺ ☺ ☻ ? ☻ ☺ - ☺
Jacob et al., 2011 ? ☺ ☺ ☻ ? ☺ ☻ ☻ ☺
Kim et al., 2011 ☺ ☺ ☺ ☺ ☺ ☻ ☺ ☻ ☺
Montagnana et al., 2011 ☺ ? ☺ ☺ ☺ ☺ ☺ ☺ ☺
Moore et al., 2008 ? ☻ ☺ ☺ ☺ ☺ ☻ - ☺
Moore et al. 2009 ☺ ? ☺ ☻ ☺ ☺ ☺ ☺ ☺
Moore et al., 2011 ? ☺ ☺ ☻ ☺ ☺ ☺ ☺ ☺
Van Gorp et al. 2011 ☺ ☺ ☺ ☺ ☺ ☺ ☻ ☻ ☺
ROMA: Risk of Ovarian Malignancy Algorithm; HE4: Human Epididymis Protein 4; CA125: Cancer Antigen 125.
















Li et al. BMC Cancer 2012, 12:258 Page 6 of 18
http://www.biomedcentral.com/1471-2407/12/258advantage of I2 was inherent independence with the
number of the studies included in the meta-analysis.
I2 estimates below 25% were regarded as low risk of het-
erogeneity, between 25% and 50% as moderate hetero-
geneity, and 50% or higher as high heterogeneity. If
there was a low level heterogeneity, univariate meta-
analysis model was used (Meta-DiSc software version
1.4 [28]). If there was a moderate to high heterogeneity,
Spearman correlation coefficients was explored. Positive
Spearman correlation coefficients between Logit(TPR)
and Logit(FPR) denoted the presence of threshold
effects (Meta-DiSc software version 1.4). Then a bivari-
ate model as well as HSROC (Hierarchical Summary
Receiver Operator Characteristics) were estimated andFigure 3 Forest Plots of paired sensitivity and specificity for ROMA.plotted; if negative, summary estimates were pooled
without HSROC [24,29]; and if zero, summary estimates
were pooled the way same as low level heterogeneity.
Influence analysis reestimated the meta-analysis by
omitting each study in turn (STATA version 10.0) to
confirm the stability of our analysis model. Publication
bias was investigated by Deek’s funnel plot as well as
asymmetry test [30]. Subgroups were analyzed hierarch-
ically by menopausal status, FIGO stages and concern of
methods of index tests. In some studies, patients with
low malignant potential tumors (LMP) or borderline
tumors (BL) were classified into EOC group. And these
studies were specifically analyzed as subgroup EOC
(LMP/BL). Subgroups with less than four studies were
Table 3 Summary estimates of ROMA for EOC and OC prediction












EOC (n = 6) [bi] 0.89 (0.84-0.93) 0.83 (0.77-0.88) 41.43 (26.17-65.57) 5.25 (3.85-7.16) 0.13 (0.08-0.20) 0.93 (0.90-0.95)=
[I2 =71.6%] [I2 =80.7%] [I2 =44.2%] [I2 =75.7%] [I2 =71.6%]
EOC- preM (n = 5) [bi] 0.82 (0.67-0.91) 0.82 (0.74-0.88) 20.55 (9.70-43.53) 4.50 (3.19-6.36) 0.22 (0.12-0.42) 0.88 (0.85-0.91) ●
[I2 =60.1%] [I2 =74.8%] [I2 =43.3%] [I2 =66.0%] [I2 =62.5%]
EOC- postM (n= 5) [bi] 0.93 (0.89-0.96) ▲ 0.79 (0.73-0.83) 47.27 (27.34-81.73) 4.33 (3.41-5.50) 0.09 (0.06-0.15) 0.89 (0.86-0.92) ●
[I2 =51.6%] [I2 =16.2%] [I2 =0.0%] [I2 =15.6%] [I2 =45.8%]
EOC- early stage (n = 3) [uni] 0.81 (0.71-0.89) ●= 0.76 (0.73-0.79) ● 17.18 (9.08-32.50) = 3.67 (2.56-5.28) 0.24 (0.15-0.38) 0.88 (0.83-0.93)=
[I2 =0.0%] [I2 =68.2%] [I2 =0.0%] [I2 =63.4%] [I2 =0.0%]
EOC- advanced stage (n= 3) [uni] 0.98 (0.94-1.00) ● 0.76 (0.73-0.79) ● 149.08 (47.80-464.95) 4.17 (3.37-5.17) 0.04 (0.01-0.13) 0.97 (0.95-1.00)
[I2 =49.8%] [I2 =68.2%] [I2 =0.0%] [I2 =55.0%] [I2 =28.1%]
EOC- methods High concern (n = 3) [uni] 0.90 (0.85-0.93) 0.87 (0.83-0.90) ?● 62.84 (3.25-112.04) 7.29(4.33-12.26) 0.12 (0.08-0.18) 0.95 (0.93-0.97)
[I2 =0.0%] [I2 =67.5%] [I2 =0.0%] [I2 =58.4%] [I2 =0.0%]
EOC- methods Low concern (n= 3) [uni] 0.89 (0.85-0.93) 0.75 (0.72-0.78) ● 29.57 (12.85-68.03) 3.74 (3.29-4.25) 0.14 (0.04-0.44) 0.91 (0.86-0.96)
[I2 =85.5%] [I2 =0.0%] [I2 =56.8%] [I2 =0.0%] [I2 =88.2%]
EOC (LMP/BL) (n = 3) [uni] 0.88 (0.84-0.92) 0.77 (0.74-0.80) 33.36 (15.02-74.06) 4.37 (2.88-6.64) 0.15 (0.11-0.20) 0.92 (0.88-0.96)
[I2 =0.0%] [I2 =89.3%] [I2 =66.8%] [I2 =84.6%] [I2 =0.0%]
OC (n= 3) [uni] 0.86 (0.82-0.89) 0.78 (0.75-0.81) 21. 436 (15.28-30.08) 4.11 (3.14-5.38) 0.19 (0.14-0.23) 0.89 (0.87-0.92)●
[I2 =0.0%] [I2 =68.9%] [I2 =0.0%] [I2 =61.8%] [I2 =0.0%]
ROMA: Risk for Ovarian Malignancy Algorithm; EOC: epithelial ovarian cancer; OC: ovarian cancer; Sen: sensitivity; spe: specificity; DOR: diagnostic odds ratio; LR+: positive likelihood ratio; LR-: negative likelihood ratio;
CI: confidence interval; bi: bivariate model; uni: univariate model (random effects model); preM: premenopausal; postM: post-menopausal; LMP: low malignant potential tumors; BL: borderline tumors. ▲ compared to
premenopausal group, = compared to advanced stage group, ? compared to methods Low concern group, and ● compared to EOC group. Cells labeled with characters have significant difference (p < 0.05) in
















Figure 4 Hierarchical summary receiver operating characteristic (HSROC) curves and results of bivariate analysis for ROMA to
predict EOC. Results of bivariate analysis: estimates of each studies (the squares), the summary point (solid circle), 95% confidence region
(the small ellipse), 95% prediction region (the big ellipse) and HSROC (solid line) were shown. Each study is represented by each square in
the meta-analysis. The size of the square indicates the size of each study.
Figure 5 Influence analysis of individual studies for performance of ROMA to predict EOC. The meta-analysis was reestimated by
omitting each study in turn. The diamonds represented the estimates of the left studies, with their 95% confidence intervals (solid) went
through their centers.
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http://www.biomedcentral.com/1471-2407/12/258analyzed with univariate model, because the bivariate
model required 4 studies at least [26]. Summary esti-
mates and 95% CIs (confidence intervals) for sensitivity,
specificity, DOR, LR± and AUC were calculated (STATA
version 10.0 [31,32]). HSROC (Hierarchical summary re-
ceiver operating characteristic curves) plots were shown
when appropriate. Comparisons between estimates of
different tests were performed with z-test.
Results
Search results
Of the 267 references identified from 6 databases, 11
articles [13-18,33-37] met the inclusion criteria and were
included in meta-analysis (Figure 1).
Characteristics of the included studies were summar-
ized (Table 1). 7792 tests from 2878 patients presentingFigure 6 Forest Plots for sensitivity and specificity of HE4 to predict Epelvic mass at risk of ovarian cancer were retrieved. Of
the 11 studies, 6 studies [15,17,18,34,36,37] enrolling
1547 patients investigated the performance of ROMA
for EOC prediction. Five studies [16,33-36] with 883
patients compared the performance of HE4 and CA125
for OC prediction. Four studies [13,15,18,36] with 715
patients compared the performance of HE4 and CA125
for EOC prediction. And 3 studies [15,18,36] (482
patients) compared the performance among ROMA,
HE4 and CA125 for EOC prediction. In all studies, the
spectrum of patients was considered representative. All
enrolled participants present pelvis mass of suspected
ovarian origin, have never received any treatment before
and plan to have a surgical intervention. The prevalence
of proven ovarian cancer across all studies ranged from
7.86% to 63.1% (overall prevalence was 18.5% for EOC).OC.
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http://www.biomedcentral.com/1471-2407/12/258The study of Holcomb and colleagues [14] had the low-
est prevalence (7.86%) for only investigating the results
of premenopausal women.Methods of index tests
All of 11 including studies measured serum HE4 and
CA125. For HE4 measurement, 8 studies [13,16-18,33,35-37]
used EIA (enzyme immunoassay), the other 3 studies
[14,15,34] employed CMIA (chemiluminescent micropar-
ticle immunoassay). For the measure of CA125, 5 studies
[14,15,17,34,37] employed CMIA, 3 studies [16,35,36]
with EIA, 3 studies [13,18,33] used RIA (radioimmuno-
assay), CLEIA (chemilumenscence enzyme immunoassay)
and ECLIA (electrochemilumenscence immunoassay)Figure 7 Forest Plots for sensitivity and specificity of CA125 to predicrespectively. CMIA, CLEIA and ECLIA belonged to che-
milumenesence immunoassays, which were higher sensi-
tive than EIA or RIA. According to Methodological
quality assessment (the 4th part of Methods section), HE4
tests with CMIA, CA125 tests with EIA and RIA were
regarded as high Concern Regarding Applicability. The
ROMA tests were considered as high Concern Regarding
Applicability when either HE4 or CA125 test was evalu-
ated as high Concern Regarding Applicability (Figure 2).Methodological quality of all included studies
Quality of included studies was assessed by the QUADAS-2
tool (Figure 2 & Table 2). Within 9 [13,14,16-18,34-37] of
11 studies, the results interpretation of index tests (HE4/t EOC.
Figure 8 Hierarchical summary receiver operating characteristic (HSROC) curves and results of bivariate analysis for HE4 and CA125 to
predict EOC. Results of bivariate analysis: estimates of each studies (the squares), the summary point (solid circle), 95% confidence region (the
ellipse) and HSROC (solid line) for HE4 (black) and CA125 (red) were shown. Each study is represented by each square in the meta-analysis. The
size of the square indicates the size of each study.
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http://www.biomedcentral.com/1471-2407/12/258CA125) were blind with reference standard test (ROMA).
The other 2 studies [15,33] were unclear. In 5 of the 11
studies [14,16,34-36] the results of index tests (HE4 and
CA125) were interpreted without knowledge of each other.
In the other 6 studies [13,15,17,18,33,37] the blindness was
unclear. So when assessing the studies with the item “Could








EOC EOC- HE4 (n = 4) [bi] 0.79 (0.74-0.84) 0.93 (0.87-0.96) 47.5
[I2 =0.0%] # [I2 =72.0%] [I2 =
EOC-CA125 (n = 4) [bi] 0.77 (0.58-0.89) 0.84 (0.76-0.90) 18.8
[I2 =90.2%] [I2 =85.3%] [I2 =
OC OC-HE4 (n= 5) [bi] 0.77(0.72-0.81) 0.89 (0.82-0.93) 25.3
[I2 =0.0%] [I2 =58.9%] [I2 =
OC-CA125 (n = 5) [bi] 0.73 (0.63-0.81) 0.86 (0.81-0.90) 17.1
[I2 =80.3%] [I2 =49.4%] [I2 =
Sen: sensitivity; spe: specificity; DOR: diagnostic odds ratio; LR+: positive likelihood
compared to CA125 with significant difference (p<0.05). All estimates in OC group h
group. I2 for estimates (sen, spe, DOR and LR±) were calculated.introduced bias?” in domain 2 of QUADAS-2, the results
showed that 5 studies [14,16,34-36] were low risk of bias, 1
study [13] was high risk of bias and 5 studies
[15,17,18,33,37] were unclear their risk of bias. Four [16-
18,34] of the total 11 studies were considered as low risk of
bias for the Patient Selection (Domain 1 of QUADAS-2) for









9 (23.87-94.90) 10.64 (5.93-19.10) 0.22 (0.17-0.29) 0.82 (0.78-0.85) #
41.3%] [I2 =71.3%] [I2 =0.0%]
6 (10.22-31.21) 4.90 (3.63-6.61) 0.27 (0.15-0.50) 0.88 (0.85-0.91)
57.4%] [I2 =56.2%] [I2 =85.2%]
7 (14.58-44.14) 6.66 (4.25-10.43) 0.26 (0.22-0.32) 0.79 (0.76-0.83) #
40.7%] [I2 =50.3%] [I2 = 0.0%]
2 (11.64-25.19) 5.35 (4.09-7.00) 0.31 (0.23-0.43) 0.89 (0.85-0.91)
7.8%] [I2 =0.0%] [I2 =75.2%]
ratio; LR-: negative likelihood ratio; CI: confidence interval; bi: bivariate model; #
ave no significant difference (p>0.05) with corresponding estimates in EOC
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http://www.biomedcentral.com/1471-2407/12/258were regarded as high risk of bias and in the other 5 studies
[13,33,35-37] the risk was unclear.Performance of ROMA for predicting EOC
Forest plots of sensitivity and specificity of ROMA for
EOC prediction were shown in Figure 3. Mean estimates
and their 95%CIs were: sensitivity 0.89 (0.84- 0.93), spe-
cificity 0.83 (0.77- 0.88) and AUC 0.93 (0.90- 0.95)
(Table 3). High level of heterogeneity lay in both sensi-
tivity (I2 = 71.6%) and specificity (I2 = 80.7%). Threshold
effect existed (Spearman correlation coefficient: 0.657,
p = 0.156). Thus bivariate model was used to pool esti-
mates. HSROC plots showed the summary estimates ofFigure 9 Forest Plots for sensitivity and specificity of HE4 to predict Osensitivity and specificity as well as the confidence and
prediction regions (Figure 4).
Subgroups analysis observed variability in pooled esti-
mates (Table 3). We have compared these estimates
between subgroups to investigate the performance of
ROMA. Across all subgroups, performance (AUCs)
of ROMA for EOC detection ranged from 0.88 to 0.97.
The ROMA performed better in EOC whole population
(AUC: 0.93, 95%CI 0.90- 0.95) than in either premeno-
pausal subgroup (EOC-preM) (AUC: 0.88, 95% CI 0.85-
0.91) or postmenopausal subgroup (EOC-postM) (AUC:
0.89, 95% CI 0.86- 0.92). And the ROMA had better per-
formence in EOC-advanced stage group (AUC: 0.88,
95% CI 0.85- 0.91) than in both EOC whole populationC.
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http://www.biomedcentral.com/1471-2407/12/258and EOC-early stage group (AUC: 0.88, 95% CI 0.83-
0.93). What’s more, the ROMA performed better in
EOC population than in OC population (AUC: 0.89, 95%
CI 0.87- 0.92).
ROMA had lower sensitivity in premenopausal sub-
group (EOC-preM) (0.82, 95%CI 0.67- 0.91) than
postmenopausal subgroup (EOC-postM) (0.93, 95%CI
0.89- 0.96). EOC group (0.83, 95% CI 0.77- 0.88) had
higher specificity than both EOC-early stage (0.76, 95%
CI 0.73- 0.79) and EOC-advanced stage (0.76, 95% CI
0.73- 0.79) groups. ROMA had higher sensitivity in
EOC-advanced stage group (0.98, 95%CI: 0.94-1.00) than
in EOC whole population (0.90, 95% CI 0.84- 0.93) and
EOC-early stage group (0.81, 95% CI 0.71- 0.89). InFigure 10 Forest Plots for sensitivity and specificity of CA125 to predaddition, we found in subgroup method with Concern
Regarding Applicability, ROMA had higher specificity
in high Concern Regarding Applicability group (EOC-
methods High concern) (0.87, 95% CI 0.83- 0.90) than
both high Concern Regarding Applicability group (EOC-
methods Low concern) (0.75, 95% CI 0.72- 0.78) and
EOC whole population. Finally, No differences were
found in other summary estimates (except AUC between
EOC and OC groups) within EOC, EOC (LMP/BL) and
OC groups (Table 3).
The appearance of the Deeks’ funnel plot for ROMA
on EOC detection was symmetrical (Additional file 2:
Figure S1), and the funnel plot asymmetry test showed
little sign of publication bias (regression coefficients wasict OC.
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http://www.biomedcentral.com/1471-2407/12/258−3.73; p = 0.617). When single study was omitted, the
summary estimates (sensitivity, specificity and DOR)
were close to those obtained with all eligible studies
(Figure 5 & Additional file 3: Table S2).Performance comparison between HE4 and CA125
Four studies [13,15,18,36] compared the performance of
HE4 and CA125 for predicting EOC (Figures 6 & 7). All
the 2 groups (EOC-HE4, EOC-CA125) were analyzed
in bivariate model (Figure 8). CA125 had a higher
AUC than HE4, while a lower specificity than HE4.
No significant differences were found within other
paired estimates (Table 4). Five studies [16,33-36] com-
pared the performance of HE4 and CA125 for predict-
ing OC (Figures 9 & 10). All the 2 groups (OC-HE4,
OC-CA125) were also analyzed via bivariate model
(Figure 11). CA125 had a higher AUC than HE4, while
no significant differences were found within other paired
estimates (Table 4).
Studies included also investigated the diagnostic value
of HE4 and CA125 in early stage of EOC, as well as dis-
tinguishing EOC from benign pelvic mass in premeno-
pausal and postmenopausal women. Because all these
settings contained less than 3 studies, we didn’t poolFigure 11 Hierarchical summary receiver operating characteristic (HS
to predict OC. Results of bivariate analysis: estimates of each studies (the s
ellipse) and HSROC (solid line) for HE4 (black) and CA125 (red) were shown
size of the square indicates the size of each study.them as subgroups but summarized their sensitivity spe-
cificity with forest plots (Additional file 4: Figure S2).
Performance comparison among ROMA, HE4 and CA125
for EOC prediction
Three studies evaluated the performance of HE4, CA125
and ROMA for EOC detection (Figure 12). All three
groups (EOC- ROMA, EOC- HE4 and EOC- CA125)
were pooled with univariate model (Figure 13 & Table 5).
Among the three tests, HE4 had the highest specificity
(0.94, 95% CI: 0.90-0.96), but a lower sensitivity (0.80,
95% CI: 0.73-0.85) than ROMA (0.86, 95% CI: 0.81-
0.91). The ROMA had a higher specificity (0.84, 95% CI:
0.79-0.88) than CA125 (0.78, 95% CI: 0.73-0.83). Mean-
while no differences were found between CA125 and
HE4, as well as between CA125 and ROMA in their
summary sensitivity. The DOR, LR ± and AUC values
were similar among the three tests (Table 5).
Discussion
Summary of main results
Our results found that, first, ROMA could help distin-
guish EOC from benign pelvic mass with a high diagnos-
tic accuracy (AUC: 0.93). The ROMA has high
sensitivity to predict advanced stage EOC than earlyROC) curves and results of bivariate analysis for HE4 and CA125
quares), the summary point (solid circle), 95% confidence region (the
. Each study is represented by each square in the meta-analysis. The
Figure 12 Forest Plots for sensitivity and specificity comparison among ROMA, HE4 and CA125 to predict EOC. A: ROMA; B: CA125; C: HE4.
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http://www.biomedcentral.com/1471-2407/12/258stage EOC and in postmenopausal women than in pre-
menopausal women. Second, although HE4 has higher
specificity than CA125 for EOC monitoring, CA125 has
better diagnosis accuracy (higher AUC) than HE4 for
EOC or OC prediction. This is based on the results of 4
studies that compare HE4 and CA125 within the same
population. Third, based on the results of comparison of
HE4, CA125 and ROMA in the same population, the
overall performance (AUC) of the three tests for EOC
prediction are similar. ROMA is less specific but more
sensitive than HE4, while both ROMA and HE4 are
more specific than CA125 for EOC monitoring.
All studies included were subjected to close scrutiny with
the QUADAS-2 tool, resulting in high quality across the
items. Heterogeneity often existed in diagnostic meta-
analysis [38], and mainly resulted from characteristics of
the study population, variations in the study design, differ-
ent statistical methods, and different covariates [39].
Within-study quality were highly concerned in this meta-
analysis. Both high level of heterogeneity in sensitivity and
specificity were found for ROMA test. The existence of
threshold effect might partially explain the heterogeneity.
Analysis of subgroups (EOC-methods high concern and
EOC-methods low concern) found the EOC-methods Highconcern group had higher specificity than both EOC-
methods Low concern group and EOC group.
In the current paper, only three studies evaluated the
diagnostic value of ROMA at early stage of EOC. The
early stage ovarian cancer usually presented non-specific
clinical manifestation, and the FIGO staging by surgery
often resulted in low prevalence of early stage EOC.
So future clinical investigations will be promising and
expectant to be prospective studies recruiting enough
patients with early stage EOC.
We analyzed the predictive value of ROMA for
patients with EOC, EOC(LMP/BL) and ovarian cancer.
No differences were found in all summary estimates
(except AUC between EOC and OC groups) of EOC,
EOC (LMP/BL) and OC groups. Although EOC
accounted for 90% of ovarian cancer, we didn’t think
ROMA could be expanded to predict ovarian cancer, for
both HE4 and CA125 were biomarkers of epithelial
ovarian cancer[2,11].
Cut-off values were variable for HE4 (70-150pM) and
ROMA (preM: 7.4-13.1%; postM: 10.9-27.7%), but con-
sistent for CA125 (35U/mL) across studies. Among the
studies included, only one study[15] used specific cut-off
values for premenopausal (70pM) and postmenopausal
Figure 13 Summary receiver operating characteristic (SROC) curves for ROMA, HE4 and CA125 to predict EOC. Results of bivariate
analysis: estimates of each studies (the squares) and SROCs (solid line) for ROMA (black), HE4 (red) and CA125 (green) were shown. Each study is
represented by each square in the meta-analysis. The size of the square indicates the size of each study. The AUCs and 95% CIs of ROMA, HE4
and CA125 are 0.92 (0.86- 0.97), 0.95 (0.92- 0.98) and 0.88 (0.81- 0.96), respectively.
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http://www.biomedcentral.com/1471-2407/12/258women (140pM). Studies found that HE4 levels in
healthy subjects were associated with age [40,41]. So it
would be essential to define a specific normal range and
cut-off value for premenopausal and postmenopausal
women respectively. For other two predictors ROMA
and CA125, it would also be indispensable for each cen-
ter to define their normal ranges and cut-off values.
Strengths and weaknesses
Except employing a comprehensive search strategy, strict








EOC- ROMA 0.86 (0.81-0.91)* 0.84 (0.79-0.88) *# 32.72
(n = 3) [uni] [I2 =75.5%] [I2 =0.0%] [I2 =6
EOC-HE4 0.80 (0.73-0.85) 0.94 (0.90-0.96) 67.99
(n = 3) [uni] [I2 =0.0%] [I2 =78.2%] [I2 =1
EOC-CA125 0.84 (0.78-0.89) 0.78 (0.73-0.83) * 19.15
(n = 3) [uni] [I2 =90.0%] [I2 =79.6%] [I2 =6
Sen: sensitivity; spe: specificity; DOR: diagnostic odds ratio; LR+: positive likelihood
(random effects model); * compared to HE4; # compared to CA125. Cells labeled wi
with the compared groups. I2 was calculated for estimates (sen, spe, DOR and LR±).of this paper also contain that only studies investigating
both the two tests (HE4 and CA125) or all three tests
(HE4, CA125 and ROMA) in a same population have
been included in tests comparisons. The latter makes
sure that the comparison takes place between studies
under the same or similar population background, thus
reduces the heterogeneity between studies [42].
The main limitations are: (1) unable to gain the un-
published paper. (2) Study number might be small. We
believe that reliability of the meta-analysis are majorly









(12.42-86.21) 5.35 (4.09-7.01) 0.17 (0.07-0.40) 0.92 (0.86-0.97)
4.4%] [I2 =0.0%] [I2 =80.5%]
(31.97-144.60) 12.21 (4.25-35.11) 0.22 (0.17-0.29) 0.95 (0.92-0.98)
9.2%] [I2 =79.0%] [I2 =0.0%]
(7.26-50.53) 3.81 (2.66-5.46) 0.23 (0.09-0.58) 0.88 (0.81-0.96)
8.8%] [I2 =41.4%] [I2 =87.6%]
ratio; LR-: negative likelihood ratio; CI: confidence interval; uni: univariate model
th characters have significant difference (p < 0.05) in corresponding estimates
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http://www.biomedcentral.com/1471-2407/12/258diagnostic value of ROMA, HE4 and CA125 in early
stage EOC have not been convincingly analyzed.
Conclusions
ROMA can help distinguish EOC from benign pelvic
mass. ROMA is less specific but more sensitive than
HE4. Both ROMA and HE4 are more specific than
CA125 for EOC prediction. CA125 has better diagnosis
accuracy than HE4 for EOC and OC prediction. ROMA
is promising predictor to replace CA125, but its
utilization requires further exploration.
Additional files
Additional file 1: Table S1. Searching strategies.
Additional file 2: Figure S1. Deeks’ funnel plot for ROMA.
Additional file 3: Table S2. Influence analysis of individual studies for
diagnostic performance of ROMA. Estimates were pooled by bivariate
model. Excluding any individual study only a small change were resulted
in the sensitivity (sen), specificity (spe) or diagnostic odds ratio (DOR)
compared with all eligible studies. All differences were not significant
(p > 0.05).
Additional file 4: Figure S2. Forest Plots for comparison between HE4
and CA125 for premenopausal and postmenopausal women and early
stage EOC groups.
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